Published: Fri, May 19, 2017
Business | By Max Garcia

Valeant Pharmaceuticals Intl Inc (VRX) Stock Rating Reaffirmed by Stifel Nicolaus


(VRX) will report its next earnings on May 09 BMO. The lowest sales estimate is $2.06 billion and the highest is $2.24 billion. The Company's year to date (YTD) performance is now negative at -8.75%. The business is expected to report its next earnings results before the market opens on Tuesday, May 9th. Analysts predict that Valeant Pharmaceuticals Intl will post $3.89 earnings per share for the current fiscal year.

Here are companies that have increased their dividend payouts for several consecutive years.

If you look at the company's income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, VRX earned gross profit of 5.97 Billion, in 2015 7.86 Billion gross profit, while in 2016 Valeant Pharmaceuticals International, Inc. It turned negative, as 82 investors sold Valeant Pharmaceuticals Intl Inc shares while 87 reduced holdings. The company had revenue of $2.11 billion for the quarter, compared to analysts' expectations of $2.17 billion. During the same quarter in the previous year, the firm posted ($1.08) EPS. The business's quarterly revenue was down 11.1% compared to the same quarter past year. UBS maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Friday, October 30. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned "Sector Perform" rating by IBC on Monday, November 30. Deutsche Bank AG decreased their price objective on shares of Valeant Pharmaceuticals Intl from $19.00 to $18.00 and set a "hold" rating for the company in a research report on Wednesday, April 19th. On Friday, August 14 the stock rating was maintained by Jefferies with "Buy". Finally, Guggenheim reaffirmed a "buy" rating on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, February 7th. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.46 on scale of 1-5.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and global copyright and trademark laws. The firm has a 50 day moving average price of $10.15 and a 200-day moving average price of $14.01. Valeant Pharmaceuticals Intl (Call) now has $4.27B valuation. The Company dividend yield observed at 4.49%. $56,301 worth of stock was bought by LECHLEITER JOHN C on Friday, March 24. The stock was sold at an average price of $11.00, for a total transaction of $199,258,752.00. Following the completion of the transaction, the chief financial officer now owns 174,000 shares of the company's stock, valued at approximately $1,865,280. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The current share price indicates that stock is -58.86% away from its one year high and is moving 62.09% ahead of its 52-week low. Buy rating has been given by 4 analysts to the company stock whereas 1 analyst given UNDERPERFORM rating to stock and 14 analysts given HOLD rating. Cubist Systematic Strategies Limited Liability Corp stated it has 0.09% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

When it comes to the Analysis of a Stock, Price Target plays a vital role. Vanguard Group has 0.01% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Public Sector Pension Investment Board boosted its position in shares of Valeant Pharmaceuticals Intl by 3.1% in the fourth quarter. ValueAct Holdings L.P. boosted its position in shares of Valeant Pharmaceuticals Intl by 20.0% in the first quarter. Over the last three months, the shares of the company have changed -40.57% and performed -16.98% over the last six months. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/05/19/rodman-renshaw-reiterates-neutral-rating-for-valeant-pharmaceuticals-intl-inc-vrx.html. To measure price-variation, we found VRX's volatility during a week at 8.05% and during a month it has been found around 7.07%.

Like this: